Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P78543
UPID:
BTG2_HUMAN
Alternative names:
BTG family member 2; NGF-inducible anti-proliferative protein PC3
Alternative UPACC:
P78543; A0A024R986; Q3KR25; Q5VUT0
Background:
Protein BTG2, also known as BTG family member 2 or NGF-inducible anti-proliferative protein PC3, plays a crucial role in cellular processes. It is an anti-proliferative protein that functions through its association with the CCR4-NOT complex, activating mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. This protein is involved in cell cycle regulation, growth arrest, and differentiation of neuronal precursors, and modulates transcription regulation mediated by ESR1. Additionally, it is linked to mitochondrial depolarization and neurite outgrowth.
Therapeutic significance:
Understanding the role of Protein BTG2 could open doors to potential therapeutic strategies.